RegeneRx

SNNLive interview with J.J. Finkelstein, President & CEO of RegeneRx Biopharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY.

Watch the video interview.

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

July 22, 2015
RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment


July 17, 2015
RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome


July 14, 2015
U.S. PTO Issues Notice of Allowance for Patent using TB4 for Improving Neurological Outcomes After Injury and Neurodegenerative Disease


June 2, 2015
Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure


May 22, 2015
RegeneRx to Present at 2 Investor Conferences


May 22, 2015
Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology


May 8, 2015
Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function